<div id="readability-page-1"><div><h2>Why Boston Scientific’s upcoming earnings are in focus</h2> <p>Boston Scientific (BSX) is back on investor radar as the company approaches its next earnings release, with analysts lifting earnings estimates and pointing to solid demand in electrophysiology and structural heart procedures.</p> <p>See our latest analysis for Boston Scientific.</p> <p>At a share price of US$97.64, Boston Scientific has seen a 5.33% 1 month share price return and a 109.84% 3 year total shareholder return. This suggests underlying momentum as upbeat earnings expectations and product news around pulsed field ablation keep attention on the name.</p> <p>If Boston Scientific’s recent move has you watching medtech more closely, this could be a good moment to scan other healthcare stocks that might fit your portfolio.</p> <p>With analyst optimism, higher earnings estimates and a strong product portfolio already well known, the key question now is whether Boston Scientific at around US$97 still offers upside or if the market is already pricing in the growth story.</p> <h2>Most Popular Narrative: 22% Undervalued</h2> <p>Compared with the last close at US$97.64, the most followed narrative points to a higher fair value, anchored in earnings expansion and margin uplift over several years.</p> <p><em>Analysts are assuming Boston Scientific's revenue will grow by 11.1% annually over the next 3 years. Analysts assume that profit margins will increase from 13.5% today to 18.7% in 3 years time.</em></p> <p>Read the complete narrative.</p> <p>Want to understand why a medtech name could justify a premium P/E, while still aiming for higher earnings and margin expansion over time? The full narrative walks through how revenue growth, margin progression and the chosen discount rate combine into that fair value number, and which earnings path needs to hold for it to stack up.</p> <p><strong>Result: Fair Value of $125.86 (UNDERVALUED)</strong></p> <p>Have a read of the narrative in full and understand what's behind the forecasts.</p> <p>However, the bullish case still has pressure points, with tariff headwinds and potential reimbursement cuts posing clear threats to margins and to volume growth expectations.</p> <p>Find out about the key risks to this Boston Scientific narrative.</p> <h2>Another View: Multiples Point To A Richer Price</h2> <p>The narrative fair value of US$125.86 suggests upside from the current US$97.64 share price, but the P/E tells a more cautious story. At 51.9x earnings versus a fair ratio of 41.3x, and above both the US Medical Equipment industry at 31.1x and peers at 41.4x, the shares carry a clear valuation premium. The question is whether you see that premium as justified by future execution or as a margin of risk if expectations cool.</p> <p>See what the numbers say about this price — find out in our valuation breakdown.</p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1b4d4a12-ab02-491b-bcb3-c677611a7948/chart/pe-multiple-vs-industry?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1b4d4a12-ab02-491b-bcb3-c677611a7948/chart/pe-multiple-vs-industry"/><figcaption>NYSE:BSX P/E Ratio as at Jan 2026</figcaption></figure><h2> Build Your Own Boston Scientific Narrative</h2> <p>If you want to stress test these assumptions yourself and prefer your own data driven view, you can build a custom Boston Scientific narrative in under three minutes: Do it your way.</p> <p>A great starting point for your Boston Scientific research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.</p> <h2>Looking for more investment ideas?</h2> <p>If Boston Scientific has sharpened your interest, do not stop here; broaden your watchlist with focused stock ideas that match how you like to invest.</p> <ul> <li>Spot potential high growth names early by scanning these 3538 penny stocks with strong financials, which already back their story with stronger financials.</li> <li>Target the intersection of algorithms and hardware through these 29 quantum computing stocks, a group of companies pushing quantum computing closer to real world use.</li> <li>Strengthen your income stream by reviewing these 12 dividend stocks with yields &gt; 3%, which might suit a yield focused approach.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p></div></div>

<p>Boston Scientific (BSX) is gaining investor attention ahead of its upcoming earnings report, with analysts raising earnings estimates due to strong demand in electrophysiology and structural heart procedures. Currently priced at $97.64, BSX has shown a 5.33% return over the past month and a 109.84% return over three years. Analysts project an 11.1% annual revenue growth and an increase in profit margins from 13.5% to 18.7% over three years, suggesting a fair value of $125.86, indicating the stock is undervalued. However, concerns about high P/E ratios and potential risks to margins remain.</p>

Assessing Boston Scientific (BSX) Valuation As Optimism Builds Ahead Of Its Next Earnings Report